Theratechnologies reports Q2 revenue $17.7M vs. $22M last year

“Demand for EGRIFTA SV remains very strong and we are witnessing record high patient enrollments. During the first half of our fiscal year, we achieved close to $37M in revenue despite an estimated negative impact of $10-$12M from the EGRIFTA SV shortage in the first quarter, which was subsequently resolved. Unique patients are back to normal levels, and new patient enrollments, another key metric, are at record highs. This, along with Trogarzo net sales which have now stabilized as expected, indicates a return to our growth trajectory for the top and bottom lines in the coming quarters,” said Paul Levesque, CEO. “We are on track to bring EGRIFTA WR, a new and improved version of this important medication for people with HIV, to the market in the third quarter, capitalizing on the momentum created in the last 12 months.”